IGF-1 LR3
Overview IGF‑1 LR3 (Insulin‑like Growth Factor 1 Long Arg3) is a synthetic analog of endogenous IGF‑1 with an extended half‑life due to modifications at the N‑terminus and a substitution of arginine at position 3. These changes significantly reduce binding to IGF binding proteins, increasing bioavailability and duration of action. IGF‑1 is a potent growth factor involved in cellular proliferation, muscle protein synthesis, and tissue regeneration. LR3 is widely studied in preclinical and laboratory contexts for its extended activity profile. Mechanism of Action (Research Context) IGF‑1 LR3 acts primarily through the IGF‑1 receptor (IGF‑1R), a transmembrane tyrosine kinase receptor that activates PI3K/Akt and MAPK pathways. These pathways are crucial for cellular growth, differentiation, and survival. The LR3 modification extends its half‑life from minutes to approximately 20–30 hours, allowing for prolonged receptor activation. This peptide influences myogenesis, satellite cell proliferation, protein synthesis, and tissue repair mechanisms. Potential Research Benefits (Reported in Literature) Muscle growth and repair: IGF‑1 LR3 is frequently studied for its role in stimulating satellite cells, promoting protein synthesis, and supporting muscle hypertrophy in preclinical models. Tissue regeneration: Research shows activity in supporting regenerative pathways in skeletal muscle, tendons, and other tissues. Enhanced recovery: Prolonged receptor activation has been associated with improved recovery time in models of injury and physical stress. Metabolic effects: IGF‑1 influences glucose uptake and insulin sensitivity pathways, making it relevant in metabolic research. Neuroprotective properties: Early data suggest IGF‑1 signaling may support neural growth and protection, including modulation of neuroinflammation and apoptosis in experimental settings. Potential Reported Side Effects / Adverse Events Reported effects from early human studies and observational contexts include transient hypoglycemia, headache, water retention, joint discomfort, and localized reactions. As IGF‑1 is a potent growth factor, prolonged or uncontrolled exposure may influence cellular proliferation and raise theoretical concerns regarding mitogenic effects. Formal safety and toxicology data remain incomplete. Reported Findings / Key Points IGF‑1 LR3 is a long‑acting analog of IGF‑1 with reduced binding to IGF binding proteins, resulting in increased bioavailability. Strongly activates IGF‑1R signaling cascades involved in anabolic and regenerative pathways. Preclinical data indicate potential applications in muscle repair, tissue regeneration, and neuroprotection. Side effects primarily relate to insulin‑like actions, fluid balance, and mitogenic potential. No regulatory approval exists for therapeutic use. Chemical / Physical Information Sequence: 83 amino acids with Arg substitution at position 3 (Long R3 modification) Approximate molecular weight: 9111 Da Class: Synthetic IGF‑1 analog General handling: store lyophilized at −20 °C, protect from light and moisture; aliquot reconstituted solutions and avoid repeated freeze–thaw cycles. Notes on Formats Studied IGF‑1 LR3 has been evaluated in research settings using injectable formulations. No approved human dosing exists. Preclinical protocols vary widely. Regulatory & Compliance Notes IGF‑1 LR3 is not approved for therapeutic use by any major health authority. It appears on the WADA Prohibited List under peptide hormones and growth factors. All procurement, storage, and research use must comply with relevant legal and institutional regulations. References (Selection) Le Roith D, et al. ‘Insulin‑like growth factors and their binding proteins.’ Ann N Y Acad Sci. Shavlakadze T, et al. IGF‑1 signaling in skeletal muscle regeneration. Velloso CP. Regulation of muscle mass by IGF‑1 signaling pathways. WADA Prohibited List — Peptide Hormones and Growth Factors. Disclaimer This is only intended for research purposes. None of this is intended for human consumption. This is only for educational and informational purposes. ——————————— Selected References PMID: 11397942 — IGF1 LR3 analog activity and extended receptor signaling PMID: 11875112 — IGF1–mediated anabolic and regenerative pathways PMID: 21636535 — Growthfactor signaling in muscle hypertrophy and repair PMID: 25540140 — Peptidebased modulation of IGF1 pathways and metabolic effects Frontiers in Endocrinology — IGF1 axis regulation and therapeutic applications Journal of Peptide Science — Growthfactor peptides and anabolic mechanisms FAQ : What is IGF1 LR3? IGF1 LR3 is a longacting analog of insulinlike growth factor1, designed for extended receptor activity and used in research to study cellular growth, recovery, and metabolic pathways. How does IGF1 LR3 work in research studies? IGF1 LR3 binds to IGF1 receptors and downstream signaling pathways such as PI3KAkt and MAPK, influencing cellular growth, protein synthesis, and nutrient utili
For research use only. Not for human consumption.